- Language: English
- 60 Pages
- Published: July 2013
- Region: Global
Therapeutic Strategies in Hypertension
- Published: August 2006
- Region: Global
- 192 Pages
- Clinical Publishing
Hypertension continues to be one of the leading causes of morbidity and mortality, significantly increasing the risk of stroke, myocardial infarction, heart failure and renal failure. It is one of the key risk factors in the metabolic syndrome, increasingly common in Western society. With such a complex aetiology, information on current antihypertensive therapy is extremely varied and dense. This new book presents a series of in-depth reviews by leading experts, bringing together in one volume the most up-to-date view on how antihypertensive therapies should be administered in a wide range of clinical settings. Incorporating the latest research on pharmacological action, clinical trials and treatment strategies, this book is one of the most complete references on antihypertensive therapy currently available and is an essential purchase for any specialist working with hypertensive patients.
- Provides a comprehensive review of current treatment options
- Latest developments reviewed from an international perspective
- Material from different sources combined in one volume for ease of access
- Specialists in hypertension, cardiology and internal medicine
- General physicians
- Hospital pharmacists
1. Is there an ideal strategy for achieving blood pressure goals?
L. M. Ruilope, G. L. Bakris
2. Should metabolic syndrome patients with ‘stage 2’ pre-hypertension receive antihypertensive therapy?
B. M. Egan
3. The presence of proteinuria and antihypertensive therapy selection
N. Khosla, P. Sarafidis, G. L. Bakris
4. Cholesterol, blood pressure and statins
R. Ramamurthy, N. J. Stone
5. Do antihypertensive agents influence lipid profiles and lipid therapy?
S. K. Arora, S. I. McFarlane
6. How strong is the evidence for a blood pressure goal of less than 130/80 mmHg for the high-risk patient?
A. Rashidi, M. Rahman
7. Approaches to cardiovascular risk reduction in patients with cardio–metabolic–renal risk
W. A. Hsueh, G. L. Bakris
8. Should there be any reluctance to initiate combination antihypertensive therapy for patients with blood pressure of 160/100 mmHg or higher?
W. J. Elliott
9. Is pulse pressure a predictor of therapeutic outcome?
G. M. London, M. E. Safar
10. Should selection of antihypertensive therapy be focused on other markers for cardiovascular risk besides blood pressure?
J. M. Flack, S. A. Nasser, S. M. O’Connor
11. Can aggressive control of blood pressure prevent progression of kidney disease?
A. E. Briglia, M. R. Weir
12. Are there consequences for attempting to achieve blood pressure goals in the first week after a stroke?
L. L. Pedelty, P. B. Gorelick
13. Diagnostic and therapeutic strategies in renal artery stenosis
S. I. McFarlane, M. O. Salifu, G. L. Bakris
G Bakris, Hypertension/Clinical Research Centre, Rush University Medical Centre, Chicago, USA